Sustaining the Investment in AIDS Research

By any criteria, AIDS must be considered the great plague of the 20th century. The epidemic's spread around the globe has been rapid. The disease has already caused more than 11.7 million deaths worldwide since its appearance in the late 1970s. With an estimated 30.6 million current infections, and new infections occurring at the rate of more than 250,000 monthly, the potential magnitude of the HIV/AIDS pandemic is truly profound. In response, the National Institutes of Health (NIH) has develo

Written byNeal Nathanson
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

By any criteria, AIDS must be considered the great plague of the 20th century. The epidemic's spread around the globe has been rapid. The disease has already caused more than 11.7 million deaths worldwide since its appearance in the late 1970s. With an estimated 30.6 million current infections, and new infections occurring at the rate of more than 250,000 monthly, the potential magnitude of the HIV/AIDS pandemic is truly profound.

In response, the National Institutes of Health (NIH) has developed a comprehensive biomedical and behavioral research program to better understand the basic biology of HIV, develop effective therapies to treat it, and design interventions to prevent transmission. For FY 1999, the U.S. Congress appropriated $1.8 billion to the NIH for the AIDS research program, which will ensure continued progress in these areas.

A dramatic development in AIDS research and care during the past two years has been the introduction of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies